MEI Pharma - MEIP Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings or view top-rated stocks.

5 brokers have issued 1 year target prices for MEI Pharma's shares. Their MEIP share price forecasts range from $1.00 to $5.00. On average, they anticipate the company's share price to reach $2.86 in the next twelve months. This suggests a possible upside of 739.8% from the stock's current price.
View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts.

MEI Pharma's stock was trading at $2.67 at the beginning of 2022. Since then, MEIP shares have decreased by 87.3% and is now trading at $0.3402.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our MEIP earnings forecast.

MEI Pharma, Inc. (NASDAQ:MEIP) posted its earnings results on Thursday, September, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.06. The firm had revenue of $11.41 million for the quarter, compared to the consensus estimate of $7.92 million. MEI Pharma had a negative trailing twelve-month return on equity of 115.15% and a negative net margin of 98.17%.

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

MEI Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.75%), Carlson Capital L P (0.86%), Two Sigma Investments LP (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.14%), Zacks Investment Management (0.08%) and Assenagon Asset Management S.A. (0.08%). Insiders that own company stock include Brian G Drazba, Daniel P Phd Gold, Frederick W Driscoll and Thomas C Reynolds.
View institutional ownership trends.

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEIP stock can currently be purchased for approximately $0.34.

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $45.34 million and generates $40.70 million in revenue each year. The company earns $-54,450,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.